End the Vaccine Carveout Act

On July 23, 2025, Representative Paul Gosar (R-AZ) introduced HR 4668, the End the Vaccine Carveout Act. The bill amends the Public Health Service Act to remove sections 2111(a)(2), (3), (5), and (6) — the provisions that currently require individuals to seek compensation through the National Vaccine Injury Compensation Program (VICP) before or instead of suing manufacturers directly. The text explicitly allows 'a civil action against a vaccine administrator or manufacturer in a State or Federal court for damages arising from such injury or death' regardless of whether a VICP petition has been filed. This is a straightforward legal change: eliminate the liability shield created by the PREP Act and the VICP exclusive-remedy provisions. The bill is in the earliest legislative stage — introduced, referred to the House Committee on Energy and Commerce, and no further action (hearings, markup, or vote) in the 10 months since introduction. A companion bill (S. 3853) exists in the Senate, referred to HELP Committee, but has identical status. The sponsors are all members of the House Freedom Caucus; no committee chairs or leadership are among the 29 cosponsors. Legislative momentum is effectively zero. This is a messaging bill that signals opposition to vaccine mandates and manufacturer immunity, but has no realistic path to enactment in the current Congress without a major change in committee leadership priorities. If enacted, the impact would be structural but not immediate for the vaccine industry. The removal of the PREP Act shield would shift the U.S. vaccine liability regime from a no-fault, government-administered compensation system (VICP, funded by a $0.75 excise tax per dose) to a traditional tort liability model. Vaccine manufacturers would face increased legal defense costs, potential punitive damages, and pressure on pricing (since the excise tax costs are no longer linked to immunity). The effect would be most severe for $MRNA (pure-play, single product line) and $PFE (large vaccine portfolio but diversified pharma), and least severe for (vaccine revenue now negligible). Real market data: All four affected tickers have declined over the trailing month, but the moves are consistent with a sector-wide pharma selloff (November 2025 election uncertainty, IRA drug pricing implementation, rate sensitivity) rather than a discrete bill-event. $MRNA dropped -7.03% over 30 days and -6.9% over 7 days — the worst performer — reflecting weak commercial prospects for COVID-19 booster demand. $PFE at $26.65 is near its 52-week low of $21.97, but there is no volume or volatility spike correlated with this bill's introduction or any committee action. The market has correctly priced this as a zero-probability near-term legislative event.